Clinical Trials Browser

Phase 2 × dalotuzumab × Clear all

NCT01609231 2020-05-04

MK-0646-025

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Phase 2 Completed

558 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT00654420 2018-08-08

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Phase 2 Completed

95 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT01234857 2017-05-31

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Phase 2 Completed

Breast Neoplasms

NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00610129 2015-11-20

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Phase 2 Completed

25 enrolled 6 charts

Neuroendocrine Tumors

NCT00799240 2014-11-07

IMPACT

Phase 2 Completed

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

NCT01175291 2011-12-05

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Colorectal Neoplasms